CSTLHealthcare · Diagnostics & ResearchThe 10 Wall Street analysts covering Castle Biosciences, Inc. hold a median 12-month price target of $46 — +28.5% from the last close. Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 90 of 100 as at 3 Nov 2026 — among the strongest tenth. Here, the model and the Street point the same way.
Consensus tells you what everyone already believes. The model scores Castle Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Momentum (91): The shares have been drifting up relative to others.
Growth (41): Sales and profits are flat, shrinking, or growing more slowly than they were.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
The bullish and bearish analyst opinions on CSTL, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
The green dot is the last close — the median target sits +28.5% from it.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 3 Aug 2026 | BTIG | Maintains | Buy | $40 → $44 |
| 25 June 2026 | Roth Capital | Initiates | Buy | $40 |
| 25 June 2026 | Roth Capital | Initiates | Buy | — |
| 13 May 2026 | BTIG | Maintains | Buy | — |
| 7 May 2026 | Baird | Maintains | Outperform | — |
| 20 Apr 2026 | Canaccord Genuity | Maintains | Buy | — |
| 27 Feb 2026 | Baird | Maintains | Outperform | — |
| 26 Jan 2026 | Guggenheim | Maintains | Buy | — |
| 12 Jan 2026 | Lake Street | Maintains | Buy | — |
| 5 Jan 2026 | Guggenheim | Maintains | Buy | — |
| 22 Dec 2025 | Canaccord Genuity | Maintains | Buy | — |
| 12 Dec 2025 | BTIG | Maintains | Buy | — |
| 5 Nov 2025 | BTIG | Maintains | Buy | — |
| 4 Nov 2025 | Baird | Maintains | Outperform | — |
| 9 Sept 2025 | Canaccord Genuity | Maintains | Buy | — |
| 21 May 2025 | Scotiabank | Maintains | Sector Outperform | — |
| 6 May 2025 | Canaccord Genuity | Maintains | Buy | — |
| 6 May 2025 | Lake Street | Maintains | Buy | — |
| 28 Feb 2025 | Baird | Maintains | Outperform | — |
| 2 Jan 2025 | Stephens & Co. | Reiterates | Overweight | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
CSTL appears in the Radar on the weeks it earns a place.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and serversIn full
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 4 Nov 2026, Castle Biosciences, Inc. returned +13.2% against +14.8% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
Cheaper than 25% of US stocks
Cheaper than 40% of US stocks
Cheaper than 39% of US stocks
Cheaper than 95% of US stocks
Higher than 69% of US stocks
Higher than 60% of US stocks
Higher than 89% of US stocks
Higher than 29% of US stocks
Higher than 23% of US stocks
Higher than 40% of US stocks
Higher than 39% of US stocks
Higher than 1% of US dividend payers
Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Castle Biosciences, Inc. has a market value of $1.1B and an enterprise value of $843.4M.
Revenue in the twelve months to 30 June 2026: $357.3M. The latest quarter grew 20.1% year on year.
Net income over the same four quarters: −$19.4M, a −5.4% net margin.
Diluted earnings per share, trailing twelve months: $−0.66.
Free cash flow in the twelve months to 30 June 2026: −$489K.
Trailing P/E: 30.5×; forward P/E: −38.2× — the forward figure prices analyst consensus estimates, not reported earnings.
Forward dividend yield: 0.00%, paying out 0% of earnings.
Castle Biosciences, Inc. employs 1,002 people — $357K of revenue per employee.
Data provided by Twelve Data
The nearest names by industry and size, scored by the same model — like for like.
Look up any of the roughly 4,600 stocks we score.
The rank is the raw material. Whether the rules would actually own Castle Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Castle Biosciences announced that its executive management is scheduled to present a company overview at the Stephens Annual Investment Conference on Nov. 18, 2026, at 12:30 p.m. Central time.
Why it matters — CSTL watchers may note the scheduled investor-conference presentation as an opportunity for management to discuss the company.
Castle Biosciences announced it will release financial results for the third quarter and nine months ended Sept. 30, 2026, after market close on Thursday, Nov. 5, 2026.
Why it matters — CSTL watchers may note the date of the company’s upcoming financial results release.
Castle Biosciences announced that three studies of its TissueCypher Barrett’s Esophagus test—two case reports and one multicenter study—will be presented at the ACG 2026 meeting. The studies describe how the test may provide progression-risk information beyond histopathology to support surveillance and treatment decisions.
Why it matters — The presentation highlights clinical research on TissueCypher’s potential to inform risk-aligned management beyond biopsy findings alone.
Castle Biosciences announced it will present new DecisionDx-Melanoma data at the EADV Congress 2026, including late-breaking results showing low-risk patients had SLN positivity below 5% and eligible patients avoiding SLNB had 99.6% five-year recurrence-free survival. A separate ePoster showed the test identifies early-stage transected melanomas with recurrence risk similar to stage IIB disease.
Why it matters — These data support expanded clinical utility of DecisionDx-Melanoma in sentinel lymph node biopsy decision-making and risk-aligned post-surgical management, which could strengthen CSTL's product evidence.
Castle Biosciences announced the publication of a study showing its TissueCypher Barrett's Esophagus Test helped guide risk-aligned management decisions at an expert surgery center in 90% of patients with non-dysplastic Barrett's esophagus. The findings appeared in a published announcement from the company.
Why it matters — The study results provide clinical evidence supporting the utility of Castle's TissueCypher test in guiding management decisions for a common patient population, potentially supporting adoption and commercial momentum.
The 10 Wall Street analysts covering Castle Biosciences, Inc. have a median 12-month price target of $46, with estimates ranging from $35 to $60. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Of the 10 analysts covering Castle Biosciences, Inc., 10 rate it a Buy, 0 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Castle Biosciences, Inc. 90 out of 100 across roughly 4,600 US stocks as at 3 Nov 2026. None of this is personal advice — it does not consider your circumstances.
As at 3 Nov 2026, Castle Biosciences, Inc. ranks 90 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Momentum (91 of 100).
No one can know that. What the data says: the median 12-month target from 10 analysts implies +28.5% from the last close, and Ticker Nerd's factor model ranks Castle Biosciences, Inc. 90 out of 100 as at 3 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
No analyst covering Castle Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for CSTL are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $35 to $60 over the next 12 months.
Castle Biosciences, Inc. returned +13.2% over the 12 months to 4 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
Castle Biosciences Inc. is a molecular diagnostics company that develops and commercializes proprietary tests designed to support clinical decision-making.
The most recent item we track (PRNewsWire, 28 Oct 2026): "Castle Biosciences to Participate in Upcoming Investor Conferences". Castle Biosciences announced that its executive management is scheduled to present a company overview at the Stephens Annual Investment Conference on Nov. 18, 2026, at 12:30 p.m. Central time.
Castle Biosciences Inc. is a molecular diagnostics company that develops and commercializes proprietary tests designed to support clinical decision-making. The company focuses primarily on dermatologic cancers, including melanoma and cutaneous squamous cell carcinoma, while also serving gastroenterology, ophthalmology, and certain mental health applications. Its portfolio includes tests used to help assess risk, refine diagnosis, and guide treatment choices through clinically actionable genomic and molecular information. Castle Biosciences works with physicians, specialty clinics, hospitals, and health systems that rely on specialized testing to better manage complex diseases and personalize care. The company’s role in the market centers on translating laboratory science into practical tools that can improve how patients are evaluated and treated across several high-need medical areas.
CEO Mr. Derek J. Maetzold · 1,002 employees · United States · https://castlebiosciences.com
